Robin L. Jones, BSc, MB, MRCP, MD, Consultant Oncologist, Royal Marsden Hospital, London, England, discusses results and takeaways from a phase III trial presented at the 2015 Connective Tissue Oncology Society (CTOS) Annual Meeting.
Robin L. Jones, BSc, MB, MRCP, MD, Consultant Oncologist, Royal Marsden Hospital, London, England, discusses results and takeaways from a phase III trial presented at the 2015 Connective Tissue Oncology Society (CTOS) Annual Meeting.
This randomized phase III trial analyzed patients with unresectable metastatic liposarcoma or leiomyosarcoma who had previously received at least two lines of chemotherapy. The primary endpoint was overall survival (OS).
In the trial, eribulin demonstrated significant benefit for patients: OS was 13.5 months compared with 11.5 months with dacarbazine.
Jones points out that this trial is significant because OS benefit is seldom seen soft tissue sarcoma studies.
PTCy Offers New Hope for Mismatched Stem Cell Transplants in Leukemia, MDS
April 13th 2024Jeff Auletta, MD, discussed how PTCy-based graft-vs-host disease prophylaxis offers a promising approach for expanding access to successful cell transplantation regardless of donor match or patient ethnicity.
Read More